Porphobilinogen Quantitative – 24 Hours Urine for Porphyria Screening

The Porphobilinogen Quantitative – 24 Hours Urine test measures the total amount of porphobilinogen, commonly abbreviated as PBG, excreted in urine during a complete 24-hour period. Porphobilinogen is an intermediate substance produced during the body's synthesis of heme. Heme is an essential component of haemoglobin and several enzymes involved in oxygen transport, energy production and drug metabolism.

Significantly increased urinary PBG can occur during attacks of selected acute hepatic porphyrias. The test may therefore form part of a biochemical evaluation for acute intermittent porphyria, hereditary coproporphyria or variegate porphyria. It is a screening or diagnostic-support investigation and cannot independently identify every type of porphyria or determine the exact genetic cause.

What Is Porphobilinogen?

Porphobilinogen is produced during a multi-step biochemical pathway that creates heme. Each step is controlled by a specific enzyme. When an enzyme has reduced activity because of an inherited or acquired disorder, pathway intermediates may accumulate in the liver, blood, urine, stool or other tissues.

In acute hepatic porphyrias, increased production of early heme precursors such as aminolevulinic acid and porphobilinogen can contribute to neurovisceral symptoms. These substances may rise substantially during an acute attack and usually fall as the episode resolves, although patterns vary between individuals and porphyria types.

What Are Porphyrias?

Porphyrias are a group of uncommon metabolic disorders caused by abnormalities in enzymes involved in heme production. They may be inherited, although some biochemical abnormalities can also be acquired. Porphyrias are broadly classified according to the main organ producing excess precursors and whether symptoms are predominantly acute neurological, abdominal or cutaneous.

Acute hepatic porphyrias primarily affect the nervous system during attacks and originate from excessive precursor production in the liver. Cutaneous porphyrias mainly cause sunlight-related skin manifestations because particular porphyrins accumulate in the skin. Some forms, including hereditary coproporphyria and variegate porphyria, can cause both acute attacks and skin symptoms.

Acute Porphyrias Evaluated with Urinary PBG

Acute Intermittent Porphyria

Acute intermittent porphyria is caused by reduced activity of hydroxymethylbilane synthase, also known as porphobilinogen deaminase. During an acute attack, urinary PBG is generally markedly elevated. Patients may experience severe abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, mental or behavioural symptoms and changes in heart rate or blood pressure.

Many people who inherit a disease-associated variant never develop attacks. Therefore, genetic susceptibility and active biochemical disease are not identical. Biochemical testing during symptoms is important when an acute attack is suspected.

Hereditary Coproporphyria

Hereditary coproporphyria is associated with reduced activity of coproporphyrinogen oxidase. It can cause acute neurovisceral attacks similar to acute intermittent porphyria. Some patients may also develop fragile or blistering skin lesions after exposure to sunlight. PBG may be increased during an acute attack but can return toward normal between episodes.

Variegate Porphyria

Variegate porphyria results from reduced protoporphyrinogen oxidase activity. It can cause acute neurological and abdominal symptoms, photosensitive skin disease or both. Urinary PBG can be raised during an acute attack, but further urine, plasma, stool or genetic testing is usually needed to distinguish it from other porphyrias.

ALA Dehydratase Deficiency Porphyria

ALA dehydratase deficiency porphyria is extremely rare. It affects an earlier step of heme synthesis and may cause acute neurological symptoms. PBG may not show the same degree of elevation as in acute intermittent porphyria because the enzyme abnormality occurs before PBG formation. Aminolevulinic acid testing may therefore be particularly relevant.

Why Is the Test Performed?

The test may be ordered when a clinician suspects acute porphyria based on recurring or unexplained neurovisceral symptoms. It may also be used when investigating an abnormal porphyrin result or monitoring a patient with a previously established diagnosis under specialist guidance.

Urinary PBG measurement is particularly valuable during an active symptomatic period because biochemical abnormalities are generally most evident at that time. Testing when the patient has no symptoms may be less sensitive for hereditary coproporphyria and variegate porphyria.

Symptoms That May Lead to Testing

A clinician may consider acute porphyria testing when a patient has severe or recurrent unexplained abdominal pain, particularly when routine imaging and gastrointestinal investigations do not identify a cause. Associated features may include nausea, vomiting, constipation, rapid heartbeat, high blood pressure, dark or reddish urine, muscle weakness, tingling, numbness, anxiety, confusion, hallucinations or seizures.

These symptoms are not specific to porphyria and are much more commonly caused by other conditions. PBG testing should be selected according to clinical assessment rather than used as a general screening test for nonspecific abdominal or neurological symptoms.

Possible Attack Triggers

In genetically susceptible individuals, an acute attack may be precipitated by selected medicines, hormonal changes, alcohol, infection, surgery, emotional or physical stress, smoking, fasting, crash dieting or very low carbohydrate intake. The triggers differ between people, and the presence of a possible trigger does not confirm porphyria.

Patients should provide a complete list of prescription medicines, non-prescription products, supplements and hormonal treatments. They should not stop essential medicines without medical guidance, as sudden discontinuation may be harmful.

Sample Required

The test requires all urine passed during a continuous 24-hour collection. The laboratory should provide an appropriate container and instructions regarding preservatives, refrigeration and light protection. Porphobilinogen and related porphyrin compounds can be affected by improper storage and exposure to light.

The total 24-hour urine volume and exact collection duration must be recorded. The laboratory may measure PBG concentration and calculate the total amount excreted during the collection period. Incomplete collection can cause a falsely low result.

How to Collect the 24-Hour Urine Sample

Starting the Collection

At the instructed starting time, empty the bladder into the toilet and do not collect this first urine. Record the exact time. This is the beginning of the 24-hour collection period.

Collecting Every Specimen

Collect every urine specimen passed after the starting time for the next 24 hours. Transfer each specimen into the approved container without contamination from stool, toilet paper, water, menstrual blood or cleaning products. Keep the collection container protected from light and stored at the temperature specified by the laboratory.

Completing the Collection

At the same time on the following day, empty the bladder one final time and add this urine to the container. Record the finishing time. Return the specimen promptly according to the laboratory's transportation instructions.

If any urine is missed, spilled or discarded, notify the laboratory. The collection may need to be restarted because missing a specimen can underestimate total PBG excretion.

Is a 24-Hour Collection Always the First Choice?

When an acute porphyria attack is suspected, many diagnostic pathways recommend a quantitative random urine PBG sample collected during symptoms because it can be obtained quickly and treatment should not be delayed. The random result is commonly normalised to urine creatinine to account for urine concentration.

A 24-hour collection may be requested according to the clinician's diagnostic plan, local laboratory method or transport requirements. However, a patient who appears seriously unwell should not delay emergency assessment or urgent biochemical testing merely to finish a 24-hour collection.

Preparation Before the Test

Follow the laboratory's preparation instructions carefully. Some testing protocols require avoidance of alcohol for at least 24 hours before and throughout the collection. Confirm this requirement with Focus Diagnostics before beginning the test.

Do not make major changes to diet, fluid intake or medication unless instructed by the doctor. Fasting or severe calorie restriction may potentially precipitate symptoms in susceptible individuals and should not be undertaken merely for sample collection.

Provide the laboratory with a list of current medicines and supplements. Some medications can affect porphyrin metabolism, while others may interfere with particular analytical methods. Inform the clinician if symptoms began after starting or changing a medicine.

Protecting the Sample from Light

Urine submitted for PBG and porphyrin testing should generally be protected from light from the time of collection. The laboratory may provide an amber container or instructions to wrap the container in opaque material. Light exposure and inappropriate temperature can affect specimen stability.

Do not assume that an ordinary transparent container is suitable. Use only the supplied or laboratory-approved collection container and follow all refrigeration or freezing instructions.

Understanding the Results

Normal or Low Result

A result within the laboratory's reference range makes an active acute porphyria attack less likely when a suitable specimen was collected during significant symptoms. However, interpretation depends on the type of porphyria, timing of collection, symptom severity, treatment and sample handling.

A normal result collected between attacks does not necessarily exclude hereditary coproporphyria or variegate porphyria. If clinical suspicion remains strong, a specialist may recommend repeat testing during symptoms or additional porphyrin, plasma fluorescence, stool or genetic investigations.

Elevated Result

A clearly elevated PBG result can support the presence of an acute hepatic porphyria in a patient with compatible symptoms. The degree of elevation and the accompanying aminolevulinic acid and porphyrin pattern help guide interpretation.

An increased result does not identify the exact porphyria type. Additional biochemical testing is usually needed to differentiate acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. Molecular genetic testing may subsequently confirm the diagnosis.

Mild or Borderline Elevation

A mild increase may be less specific than a marked elevation and should be interpreted cautiously. Collection errors, urine concentration, analytical variation, liver disease, treatment status and other factors may affect results. Repeat or confirmatory testing may be recommended.

Related Tests

• Quantitative random urine porphobilinogen
• Urine aminolevulinic acid
• Quantitative urine porphyrin fractionation
• Plasma porphyrins or plasma fluorescence scanning
• Faecal porphyrin analysis
• Blood lead testing when clinically indicated
• Liver and kidney-function tests
• Serum electrolytes, especially sodium during an acute illness
• Enzyme testing in selected circumstances
• Molecular genetic testing for porphyria-associated genes

Test Limitations

This test is primarily useful for evaluating acute hepatic porphyrias associated with increased PBG. It is not a complete screening test for every porphyria. Some cutaneous and erythropoietic porphyrias may require different specimens and analytes.

A negative result may occur when testing is performed outside a symptomatic episode, after treatment or when the disorder does not cause significant PBG elevation. An elevated result must be confirmed and characterised using an appropriate biochemical testing pathway.

Improper light protection, incorrect storage, inaccurate collection duration or missed urine can compromise the result. Laboratory-specific reference intervals and units must always be used.

When Is Urgent Medical Attention Required?

Acute porphyria can potentially cause severe neurological and metabolic complications. Seek urgent medical care for severe persistent abdominal pain with vomiting, progressive muscle weakness, difficulty breathing, confusion, seizures, fainting, severe agitation or rapidly worsening neurological symptoms.

Patients with a known acute porphyria should follow their specialist's emergency plan. Do not wait for completion of a 24-hour urine collection when severe symptoms are present. Urgent random urine PBG testing and immediate clinical assessment may be more appropriate.

Clinical Interpretation Note

The Porphobilinogen Quantitative 24-Hour Urine test measures PBG excretion as part of a porphyria evaluation. A marked increase during compatible symptoms can support acute hepatic porphyria, while a normal result during a well-documented severe attack makes selected acute porphyrias less likely. The result cannot identify the exact porphyria type without further biochemical or genetic testing.

Booking the Porphobilinogen Quantitative 24-Hour Urine Test

The Porphobilinogen Quantitative – 24 Hours Urine for Porphyria Screening test is available through Focus Diagnostics for ₹600. Before beginning the collection, confirm the correct container, alcohol restriction, preservative, light-protection requirement, storage temperature and return process. This information is educational and does not replace personalised advice from a physician, neurologist, gastroenterologist, hepatologist or metabolic specialist.